Good morning, everyone, welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that oh-so-familiar routine of meetings, deadlines, and teleconferences has predictably returned. But what can you do? The world keeps spinning, wobbly as it may appear. So to cope, we are firing up our trusty coffee kettle and brewing a few cups of stimulation. Support your neurons today. Meanwhile, here are a few tidbits to get you started. Hope your day goes well and, of course, do keep in touch. We appreciate your tips and insights. …

Regeneron Pharmaceuticals (REGN) will pay $800 million to Alnylam Pharmaceuticals (ALNY) to leverage its gene silencing technique for developing new therapies and become its exclusive partner for new drugs focused on the central nervous system or the eye, STAT reports. The collaboration will combine Regeneron’s genetic research with Alnylam’s technology, which centers on RNA interference, or RNAi, technology that uses small bits of the chemical messenger RNA to block genetic messages from cells. Regeneron and Sanofi (SNY) are ending most of an RNAi pact, PMLive notes.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy